Process for preparing cyclohexanediacetic acid monoamide
    1.
    发明授权
    Process for preparing cyclohexanediacetic acid monoamide 失效
    环己烷二乙酸单酰胺的制备方法

    公开(公告)号:US07381823B2

    公开(公告)日:2008-06-03

    申请号:US10599009

    申请日:2005-03-17

    IPC分类号: C07D221/20 C07C53/134

    CPC分类号: C07D221/20

    摘要: A new process is described for synthesising cyclohexanediacetic acid monoamide, a key compound in the synthesis of grabapentin precursors. The process of the invention is characterised by reacting cyclohexanone with cynoacetamide and immediately after, with a suitable malonic acid ester. A new intermediate (5-cyano-2,4-dioxo-3-azaspiro[5,5]undecane-1-carboxylic acid ester) is obtained which is convertible, under mild reaction conditions, into cyclohexanediacetic acid monoamide.

    摘要翻译: 描述了合成环己烷二乙酸单酰胺的新方法,其是在加巴喷丁前体的合成中的关键化合物。 本发明的方法的特征在于使环己酮与鲸蜡醇乙酰胺反应,并立即与合适的丙二酸酯反应。 得到新的中间体(5-氰基-2,4-二氧代-3-氮杂螺[5,5]十一碳烷-1-羧酸酯),其在温和的反应条件下可转化成环己烷二乙酸单酰胺。

    Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use
    2.
    发明授权
    Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use 失效
    细胞有丝分裂和机制的肽拮抗剂及其治疗用途

    公开(公告)号:US06245742B1

    公开(公告)日:2001-06-12

    申请号:US08930616

    申请日:1997-10-15

    IPC分类号: A61K3800

    摘要: The present invention relates to peptides and peptidomimetic compounds and pharmaceutical compositions containing them as useful pharmacological agents in the control or treatment of proliferative diseases such as cancer, against tumor growing and/or tumoral metastasis, and psoriasis and in the control or treatment of inflammatory, allergic, autoimmune, viral, and cardiovascular diseases. These new compounds have the unique property to inhibit the recognition of several phosphotyrosine containing motifs within all the cellular receptors and cytosolic transducers by a wide spectrum of SH2 domains contained in cytosolic transducers and other effector proteins laying along different pathways of the signal transduction process and with a particularly high affinity for the SH2 domain of the adaptor transducer Grb2, a key element along the pathway to mitogenesis and motogenesis, this last activity leading to invasiveness and to metastasis. The invention also relates to methods for production of the compounds and methods of treatment employing the compounds.

    摘要翻译: 本发明涉及肽和拟肽化合物和药物组合物,其含有它们作为控制或治疗增殖性疾病如癌症,抗肿瘤生长和/或肿瘤转移以及牛皮癣以及控制或治疗炎症, 过敏性,自身免疫性,病毒性和心血管疾病。 这些新化合物具有独特的性质,可以通过广泛的SH2结构域抑制所有细胞受体和细胞溶质转导体中识别的含有多种含磷酸酪氨酸基序,这些SH2结构域包含在信号转导过程不同途径的细胞溶质转导和其他效应蛋白中, 对于适应器传感器Grb2的SH2结构域特别高的亲和力,Grb2是沿着有丝分裂和发育的途径的关键因素,这是导致侵袭和转移的最后一个活动。 本发明还涉及化合物的制备方法和使用该化合物的处理方法。

    Purification 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid
    3.
    发明授权
    Purification 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid 有权
    从4-氮杂 - 雄甾烷-17-酸酸中纯化4-氮杂 - 雄甾-1-烯-17-酸

    公开(公告)号:US08664395B2

    公开(公告)日:2014-03-04

    申请号:US13257865

    申请日:2009-04-02

    IPC分类号: C07D221/18 A61K31/435

    CPC分类号: C07J73/005

    摘要: The present invention relates to a process of separation of 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid, which brings to 4-aza-androst-1-ene-17-oic containing less than 0.05% w/w of 4-aza-androstan-17-oic acid, with high yield and productivity. In particular, the present invention relates to a process for the separation of 4-aza-androstan-17-oic acid from 4-aza-androst-1-ene-17-oic acid, comprising the steps of treating the crude 4-aza-androst-1-ene-17-oic acid with formic acid and recovering the purified 4-aza-androst-1-ene-17-oic acid containing 4-aza-androstan-17-oic acid in w/w % less than 0.05%.

    摘要翻译: 本发明涉及从4-氮杂 - 雄甾烷-17-酸分离4-氮杂 - 雄甾-1-烯-17-酸的方法,其使4-氮杂 - 雄甾-1-烯-17-酸 含有小于0.05%w / w的4-氮杂 - 雄甾烷-17-酸的2-羟基苯甲酸,产率高,生产率高。 特别地,本发明涉及从4-氮杂 - 雄甾-1-烯-17-酸酸分离4-氮杂 - 雄甾烷-17-酸的方法,包括以下步骤:将粗制4-氮杂 - 雄甾-1-烯-17-酸与甲酸反应,并回收纯化的含有4-氮杂 - 雄甾烷-17-酸的4-氮杂 - 雄甾-1-烯-17-酸,w / w% 0.05%。

    PROCESS FOR PREPARING CYCLOHEXANEDIACETIC ACID MONOAMIDE
    4.
    发明申请
    PROCESS FOR PREPARING CYCLOHEXANEDIACETIC ACID MONOAMIDE 失效
    制备环己酸单丁酰胺的方法

    公开(公告)号:US20070208175A1

    公开(公告)日:2007-09-06

    申请号:US10599009

    申请日:2005-03-17

    IPC分类号: C07D227/093

    CPC分类号: C07D221/20

    摘要: A new process is described for synthesising cyclohexanediacetic acid monoamide, a key compound in the synthesis of grabapentin precursors. The process of the invention is characterised by reacting cyclohexanone with cynoacetamide and immediately after, with a suitable malonic acid ester. A new intermediate (5-cyano-2,4-dioxo-3-azaspiro[5,5]undecane-1-carboxylic acid ester) is obtained which is convertible, under mild reaction conditions, into cyclohexanediacetic acid monoamide.

    摘要翻译: 描述了合成环己烷二乙酸单酰胺的新方法,其是在加巴喷丁前体的合成中的关键化合物。 本发明的方法的特征在于使环己酮与鲸蜡醇乙酰胺反应,并立即与合适的丙二酸酯反应。 得到新的中间体(5-氰基-2,4-二氧代-3-氮杂螺[5,5]十一碳烷-1-羧酸酯),其在温和的反应条件下可转化成环己烷二乙酸单酰胺。

    PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID
    5.
    发明申请
    PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID 有权
    来自4-AZA-ANDROSTAN-17-OIC酸的4-AZA-ANDROST-1-ENE-17-OIC酸的纯化

    公开(公告)号:US20120029196A1

    公开(公告)日:2012-02-02

    申请号:US13257865

    申请日:2009-04-02

    IPC分类号: C07D221/18

    CPC分类号: C07J73/005

    摘要: The present invention relates to a process of separation of 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid, which brings to 4-aza-androst-1-ene-17-oic containing less than 0.05% w/w of 4-aza-androstan-17-oic acid, with high yield and productivity. In particular, the present invention relates to a process for the separation of 4-aza-androstan-17-oic acid from 4-aza-androst-1-ene-17-oic acid, comprising the steps of treating the crude 4-aza-androst-1-ene-17-oic acid with formic acid and recovering the purified 4-aza-androst-1-ene-17-oic acid containing 4-aza-androstan-17-oic acid in w/w % less than 0.05%.

    摘要翻译: 本发明涉及从4-氮杂 - 雄甾烷-17-酸分离4-氮杂 - 雄甾-1-烯-17-酸的方法,其使4-氮杂 - 雄甾-1-烯-17-酸 含有小于0.05%w / w的4-氮杂 - 雄甾烷-17-酸的2-羟基苯甲酸,产率高,生产率高。 特别地,本发明涉及从4-氮杂 - 雄甾-1-烯-17-酸酸分离4-氮杂 - 雄甾烷-17-酸的方法,包括以下步骤:将粗制4-氮杂 - 雄甾-1-烯-17-酸与甲酸反应,并回收纯化的含有4-氮杂 - 雄甾烷-17-酸的4-氮杂 - 雄甾-1-烯-17-酸,w / w% 0.05%。